TABLE 2.

In vivo neutralizing activity of octameric sCD46-C4bpα and monomeric sCD46 proteins^a

Inoculated virus	Treatment	Death ratiob	Mean survival time (days)
MV	PBS	6/6	7.6
	sCD46	3/4	13.0
	sCD46-C4bpα	0/6	—c
CDV	PBS	3/3	7.3
	sCD46	3/3	7.6
	sCD46-C4bpα	3/3	7.7

^aSuckling transgenic CD46 mice (2 to 3 days old) were inoculated intracranially with either 11 μg (i.e., 35 pmol) of octameric sCD46-C4bpα (equivalent to 280 pmol of monovalent CD46) or 24 μg (i.e., 400 pmol) of monomeric sCD46 or PBS together with 6,000 infectious units of either MV or CDV. Animals were observed for clinical symptoms and death daily during 10 weeks. 

^bNumber of mice that died/number of mice inoculated. 

^c—, all mice survived.